Fintel reports that on September 29, 2025, B. Riley Securities maintained coverage of Madrigal Pharmaceuticals (NasdaqGS:MDGL ...
Discover why MDGL's Rezdiffra leads in MASH therapy with rapid US and EU expansion. Learn about growth potential and risks.
In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.
B. Riley raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $560 from $460 and keeps a Buy rating on the shares following a ...
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on AnaptysBio today and set a price target of $57.00. The company’s shares closed yesterday at $23.27. Take advantage of TipRanks Premium ...
Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.
Mergers and acquisitions activity has picked up in 2025, and Goldman Sachs thinks there's more dealmaking ahead in the coming ...
The following are the 48 stocks in the basket with their M&A rank. A rank of 1 denotes analysts see a 30%-50% probability of ...
Santa Cruz Sentinel on MSN
Golden State Warriors sign Alex Toohey, Pat Spencer to two-way contracts | Local Roundup
Australian forward Alex Toohey, 21, and 6-3 guard Pat Spencer, 29, to two-way contracts, the team announced Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback